General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Multiple Myeloma
Last updated February 25, 2022
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Multiple Myeloma
Last updated February 25, 2022
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Multiple Myeloma (newly diagnosed)
Last updated February 25, 2022
Status:
Concluded with an LOI
Manufacturer:
United Therapeutics
Indication:
High-risk Neuroblastoma in patients in their first relapse or determination of refractory disease, in combination with irinotecan, temozolomide, and granulocyte macrophage colony-stimulating factor
Last updated February 24, 2022
Status:
Concluded without agreement
Manufacturer:
Otsuka Canada Pharmaceutical Inc.
Indication:
Hyperkalemia
Last updated February 18, 2022
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma, locally advanced unresectable or metastatic, in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients (First-line treatment)
Last updated February 11, 2022
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Extensive stage small cell lung cancer (ES-SCLC), first-line treatment, in combination with a platinum-based chemotherapy and etoposide
Last updated February 11, 2022
Entuzity KwikPen (human insulin)
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated February 7, 2022
Status:
Concluded with an LOI
Manufacturer:
Boehringer Ingelheim (Canada) Ltd.
Indication:
Chronic fibrosing interstitial lung diseases
Last updated February 5, 2022
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Spinal Muscular Atrophy
Last updated January 19, 2022